Auro Laboratories Limited (530233) Fair Value & Analysis

Other · IN · Market cap ₹531M

Below-average quality, and screening another 69% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (₹95.62). The favourable scenario is already priced in.
• Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
• A fairly wide model range (₹52.81 to ₹95.62) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.

How to read this chart

60‑month range ₹54.08 – ₹302.05 · fair‑value band ₹52.81 – ₹95.62 · the ₹235.50 price screens above the ₹73.55 fair value. Dashed = 300-day average. As of Aug 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Auro Laboratories Limited (530233) currently trades at ₹235.50, while our model-based Fair Value estimate is ₹73.55, implying the stock looks roughly 68.8% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Auro Laboratories Limited generated revenue of ₹464M at a net margin of 11.1%. Revenue grew 40.8% year over year. It earns a return on equity of 22.8%. Net debt stands at ₹619M. Fundamentals as of Aug 19, 2026

Our scenario range runs from ₹52.81 (bear case) to ₹95.62 (bull case); at ₹235.50, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 48% above its 52-week low, currently above its 200-day average. For context, the median of 10 Other peers we cover trades at -24% fair-value upside, at -69%, 530233 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (₹93.24) versus Earnings-Based (₹14.51). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India.

Full company description

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Auro Laboratories Limited reported revenue of ₹307M in FY2026 versus ₹509M in FY2022, a compound −11.8%/yr. Reported net income was ₹35.3M in FY2026, compounding +5.6%/yr from FY2022.

530233 screens 69% overvalued. Compare with Federal Home Loan Mortgage Corporation →

Peer Group

Other · 318 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Other median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Other stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).

Explore undervalued stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.